Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor


  1. Published

    Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV.

    Gram, D. X., Hansen, A. J., Deacon, Carolyn F., Brand, C. L., Ribel, U., Wilken, M., Carr, R. D., Svendsen, O. & Ahrén, B., 2005, In: European Journal of Pharmacology. 509, 2-3, p. 211-7 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published
  3. Published

    Effect of Vildagliptin on Glucagon Concentration During Meals in Patients with Type 1 Diabetes

    Foley, J. E., Ligueros-Saylan, M., He, Y. L., Holst, Jens Juul, Deacon, Carolyn F., Dunning, B. E., Leone-Jones, A., Yu, T. & Kelley, D. E., 2008, In: Hormone and Metabolic Research. 40, 10, p. 727-730 3 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes

    Foley, J. E., Ligueros-Saylan, M., He, Y., Holst, Jens Juul, Deacon, Carolyn F., Dunning, B. E., Leone-Jones, A., Yu, T. & Kelley, D. E., Oct 2008, In: Hormone and Metabolic Research. Supplement. 40, 10, p. 727-30 4 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men

    Eelderink, C., Noort, M. W. J., Sozer, N., Koehorst, M., Holst, Jens Juul, Deacon, Carolyn F., Rehfeld, Jens Frederik, Poutanen, K., Vonk, R. J., Oudhuis, L. & Priebe, M. G., 2017, In: European Journal of Nutrition. 56, 3, p. 1063-1076 14 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    The structure of wheat bread influences the postprandial metabolic response in healthy men

    Eelderink, C., Noort, M. W. J., Sozer, N., Koehorst, M., Holst, Jens Juul, Deacon, Carolyn F., Rehfeld, Jens Frederik, Poutanen, K., Vonk, R. J., Oudhuis, L. & Priebe, M. G., Oct 2015, In: Food & Function. 6, 10, p. 3236-48 13 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review

    Deacon, Carolyn F., Jan 2011, In: Diabetes, Obesity and Metabolism. 13, 1, p. 7-18 12 p.

    Research output: Contribution to journalReviewResearchpeer-review

  8. Published

    Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors

    Deacon, Carolyn F., 2020, In: Peptides. 125, 7 p., 170196.

    Research output: Contribution to journalReviewResearchpeer-review

  9. Published

    Commentary: Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?

    Deacon, Carolyn F., 2012, In: Diabetes. 61, 9, p. 2219-2220

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Physiology of incretins in health and disease

    Deacon, Carolyn F. & Ahren, B., 2011, In: Review of Diabetic Studies. 8, 3, p. 293-306 14 p.

    Research output: Contribution to journalReviewResearchpeer-review

  11. Published

    DPP-4 inhibition – advances in our understanding of diabetes management

    Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: European Endocrinology. 4, p. 47-49

    Research output: Contribution to journalReviewResearch

  12. Published

    Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

    Deacon, Carolyn F., 2019, In: Frontiers in Endocrinology. 10, 14 p., 80.

    Research output: Contribution to journalReviewResearchpeer-review

  13. Published

    Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.

    Deacon, Carolyn F. & Lebovitz, H., 2016, In: Diabetes, Obesity and Metabolism. 18, 4, p. 333-347 15 p.

    Research output: Contribution to journalReviewResearchpeer-review

  14. Published

    A comparative review of DPP-4 inhibitors and sulphonylureas

    Deacon, Carolyn F. & Lebovitz, H., 2016, In: Diabetes, Obesity and Metabolism. 18, p. 333-347

    Research output: Contribution to journalJournal articleResearchpeer-review

  15. Published

    Potential cardiovascular effects of incretin-based therapies

    Deacon, Carolyn F. & Marx, N., 2012, In: Expert Review of Cardiovascular Therapy. 10, p. 337-351

    Research output: Contribution to journalReviewResearchpeer-review

  16. Published

    Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis

    Deacon, Carolyn F., Mannucci, E. & Ahren, B., 2012, In: Diabetes, Obesity and Metabolism Online. 14, 8, p. 762-767

    Research output: Contribution to journalReviewResearchpeer-review

  17. Published

    Circulation and degradation of GIP and GLP-1

    Deacon, Carolyn F., 2004, In: Hormone and Metabolic Research. 36, p. 761-765

    Research output: Contribution to journalJournal articleResearchpeer-review

  18. Published

    Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

    Deacon, Carolyn F. & Holst, Jens Juul, 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-140 8 p.

    Research output: Contribution to journalReviewResearchpeer-review

  19. Published

    A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomised controlled trials

    Deacon, Carolyn F., 2018, In: Diabetes, Obesity and Metabolism. 20, Suppl. 1, p. 34-46

    Research output: Contribution to journalReviewResearchpeer-review

  20. Published

    Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

    Deacon, Carolyn F., 2020, In: Nature Reviews Endocrinology. 16, 11, p. 642-653

    Research output: Contribution to journalReviewResearchpeer-review

  21. Published

    What do we know about the secretion and degradation of incretin hormones?

    Deacon, Carolyn F., 2005, In: Regulatory Peptides. 128, 2, p. 117-24 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  22. Published

    Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

    Deacon, Carolyn F. & Holst, Jens Juul, Oct 2013, In: Expert Opinion on Pharmacotherapy. 14, 15, p. 2047-58 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  23. Published

    DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes

    Deacon, Carolyn F., Carr, R. D. & Holst, Jens Juul, 2008, In: Frontiers in Bioscience. 13, p. 1780-94 14 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  24. Published

    Differential regional metabolism of glucagon in anesthetized pigs.

    Deacon, Carolyn F., Kelstrup, M., Trebbien, R., Klarskov, L., Olesen, M. & Holst, Jens Juul, 2003, In: American Journal of Physiology: Endocrinology and Metabolism. 285, 3, p. E552-60

    Research output: Contribution to journalJournal articleResearchpeer-review

  25. Published

    Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

    Deacon, Carolyn F., Ahrén, B. & Holst, Jens Juul, 2004, In: Expert Opinion on Investigational Drugs. 13, 9, p. 1091-102 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  26. Published

    A review of dipeptidyl peptidase-4 inhibitors: Hot topics from randomized controlled trials

    Deacon, Carolyn F., Feb 2018, In: Diabetes, Obesity and Metabolism. 20, p. 34-46 13 p.

    Research output: Contribution to journalReviewResearchpeer-review

  27. Published

    Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

    Deacon, Carolyn F. & Holst, Jens Juul, 2005, In: International Journal of Biochemistry & Cell Biology. 38, 5-6, p. 831-44 13 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  28. Published

    Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

    Deacon, Carolyn F., 2007, In: Diabetes, Obesity and Metabolism. 9 Suppl 1, p. 23-31 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  29. Published

    Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes

    Deacon, Carolyn F., Feb 2018, In: Peptides. 100, p. 150-157 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  30. Published

    Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

    Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Advances in Therapy. 26, 5, p. 488-99 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  31. Published

    GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.

    Deacon, Carolyn F., Plamboeck, A., Møller, Søren & Holst, Jens Juul, 2002, In: American Journal of Physiology: Endocrinology and Metabolism. 282, 4, p. E873-9

    Research output: Contribution to journalJournal articleResearchpeer-review

  32. Published

    Therapeutic strategies based on glucagon-like peptide 1.

    Deacon, Carolyn F., 2004, In: Diabetes. 53, 9, p. 2181-9 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  33. Published

    GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.

    Deacon, Carolyn F., Plamboeck, A., Rosenkilde, Mette, de Heer, J. & Holst, Jens Juul, 2006, In: American Journal of Physiology: Endocrinology and Metabolism. 291, 3, p. E468-75

    Research output: Contribution to journalJournal articleResearchpeer-review

  34. Published

    Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

    Deacon, Carolyn F., 2008, In: Current Opinion in Investigational Drugs. 9, 4, p. 402-13 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  35. Published

    Potential of liraglutide in the treatment of patients with type 2 diabetes

    Deacon, Carolyn F., 2009, In: Vascular Health and Risk Management (Online). 5, 1, p. 199-211 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  36. Published

    Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.

    Deacon, Carolyn F. & Holst, Jens Juul, 2002, In: Biochemical and Biophysical Research Communications. 294, 1, p. 1-4 3 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  37. Published

    Immunoassays for the incretin hormones GIP and GLP-1

    Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Best Practice & Research: Clinical Endocrinology & Metabolism. 23, 4, p. 425-32 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  38. Published

    MK-431 (Merck).

    Deacon, Carolyn F., 2005, In: Current Opinion in Investigational Drugs. 6, 4, p. 419-26 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  39. Published

    Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

    Deacon, Carolyn F., 2007, In: Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  40. Published

    Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

    Deacon, Carolyn F. & Holst, Jens Juul, Jan 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-40 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  41. Published

    Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide

    Deacon, Carolyn F., Nauck, M. A., Meier, J., Hücking, K. & Holst, Jens Juul, 2000, In: Journal of Clinical Endocrinology and Metabolism. 85, p. 3575-3581

    Research output: Contribution to journalJournal articleResearchpeer-review

  42. Published

    Human colon produces fully processed glucagon-like peptide-1 (7-36 amide).

    Deacon, Carolyn F., Johnsen, A. H. & Holst, Jens Juul, 1995, In: FEBS Letters. 372, p. 269-272.

    Research output: Contribution to journalJournal articleResearchpeer-review

  43. Published

    Degradation of glucagon-like peptide-1 in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo.

    Deacon, Carolyn F., Johnsen, A. H. & Holst, Jens Juul, 1995, In: Journal of Clinical Endocrinology and Metabolism. 80, p. 952-957

    Research output: Contribution to journalJournal articleResearchpeer-review

  44. Published

    Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

    Deacon, Carolyn F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O. & Holst, Jens Juul, 1998, In: Diabetologia. 41, p. 271-278

    Research output: Contribution to journalJournal articleResearchpeer-review

  45. Published

    Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects.

    Deacon, Carolyn F., Nauck, M. A., Nielsen, M. T., Pridal, L. & Holst, Jens Juul, 1995, In: Diabetes. 44, p. 1126-1131

    Research output: Contribution to journalJournal articleResearchpeer-review

  46. Published

    Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

    Deacon, Carolyn F., Danielsen, P., Klarskov, L., Holst, Jens Juul & Olesen, M., 2001, In: Diabetes. 50, p. 1588-1597

    Research output: Contribution to journalJournal articleResearchpeer-review

  47. Published

    Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

    Deacon, Carolyn F., Hughes, T. E. & Holst, Jens Juul, 1998, In: Diabetes. 47, p. 764-769

    Research output: Contribution to journalJournal articleResearchpeer-review

  48. Published

    Glucagon-like peptide-1: A basis for new approaches to the management of Diabetes

    Deacon, Carolyn F., Holst, Jens Juul & Carr, R. D., 1999, In: Drugs of Today. 35, p. 159-170

    Research output: Contribution to journalJournal articleResearchpeer-review

  49. Published

    Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

    Deacon, Carolyn F., Wamberg, S., Bie, P., Hughes, T. E. & Holst, Jens Juul, Feb 2002, In: Journal of Endocrinology. 172, 2, p. 355-62 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  50. Published

    Glucagon-like peptide-1: a basis for new approaches to the management of diabetes

    Deacon, Carolyn F., Holst, Jens Juul & Carr, R. D., Mar 1999, In: Drugs of Today. 35, 3, p. 159-70 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

ID: 9220